shadow

Corporate Overview

Kent Imaging Inc. is a privately held medical device company headquartered in Calgary, Alberta. Founded in 2006, Kent assembled an international team of engineers, scientists and practitioners to address the development and commercialization of healthcare related devices. At present the company is working to commercialize two spectroscopy-based technologies, one to predict tissue viability through measurement of the blood oxygen level in tissue, and another to detect the presence of skin cancer. Both these technologies are based upon intellectual property licensed from the National Research Council of Canada's Institute of Biodiagnostics. Furthest in development is the Tissue Viability camera, which utilizes a specialized imaging system enabling emergency doctors and surgeons to survey injured or reconstructed tissue and determine the state of health of the tissue. This system gives the clinician a view into the future outcome which is not available using current methods of visual inspection. Having a multidisciplinary staff allows Kent to internally design and control all aspects of the development process, including electronics, optics, software, industrial design and regulatory affairs.

History

Although incorporated in 2006, the essence of Kent Imaging began 2 years earlier when the CEO and founder was working in the medical device industry and saw the potential growth of this market. An opportunity presented itself to review some of the platform technologies in development at Canada’s National Research Council. The technology was selected and a core group of developers were assembled; technical reviews began along with business and development planning. Upon incorporation, financing was raised and the license agreements were executed providing Kent with worldwide exclusive rights to the patented NRC technology. The Tissue Viability camera system began development in 2006 and has since gone through three iterations to arrive at the pre-commercialization version.

The Future

Working with clinicians and through market research as well as reflecting on NRC’s past experience Kent is targeting two areas for the initial use of the camera system: burns and reconstructive breast surgery. In both cases clinical work is proceeding and the markets are significant. As this moves forward, our development team will begin to expand the platform technology to address other areas such as Diabetes, Pressure Ulcers (bed sores), Plastic Surgery, Transplant Surgery, detection of Retinopathy and Glaucoma. The future holds many opportunities for this platform technology and they will expand even more as we work to improve the portability of the system.